TiumBio Co., Ltd. announced that the company presented clinical outcomes of its hemophilia treatment, TU7710, at the 32ndCongress of the International Society on Thrombosis and Haemostasis (ISTH) and embarked on building new global partnerships. TiumBio is currently conducting a double-blind, placebo-controlled Phase 1a clinical trial evaluating the pharmacokinetics, pharmacodynamics, and safety of TU7710 in healthy adult males. At the conference, interim results were presented for a total of 32 participants across cohorts ranging from 100 mg/kg (Cohort 1) to 800 mg/kg (Cohorts 4) dosinggroups.

In the clinical results presented at the ISTH conference, TU7710 showed an average half-life ranging from 10.4 to 16.6 hours across dosage groups. This is 5 to 7 times longer than that of NovoSeven, a conventional hemophilia drug for patients with neutralizing antibodies against standard therapies, which has a known half-life of 2.3 hours. Furthermore, no serious adverse and thromboembolic events occurred, and most of adverse events were mild.

Half-life refers to the time it takes for the blood concentration of a drug to decrease by half and is related to the sustainability of drug efficacy. Due to its short half-life, when bleeding occurs, hemophilia A or B patients with inhibitors are recommended to receive NovoSeven every two hours until hemostasis is achieved, which places a burden on patients and healthcare providers. TiumBio plans to initiate a Phase 1b clinical trial of TU7710 in hemophilia patients in Europe in the second half of this year.